June 13, 2002 — Advectus Life Sciences Inc. said a University of Kentucky research center will perform studies on the company’s nanoparticle-based process of treating brain tumors, according to a news release.
The university’s Research Foundation Center for Pharmaceutical Science and Technology will conduct manufacturing and stability studies registered by the U.S. Food and Drug Administration. The work is designed to move Advectus’ patented technology from pre-clinical tests to clinical trials in humans, the company said.
The technology uses nanoparticles composed of a polymeric material. An anti-cancer drug is absorbed or incorporated into the nanoparticle for delivery across the blood brain barrier. The patented nanoparticle technology has shown in preclinical tests to deliver doxorubicin, a highly potent, anti-tumor drug that normally does not cross the blood-brain barrier.